<?xml version="1.0" encoding="UTF-8"?>
<p>Treatment is mainly supportive, as no antiviral treatment has been clinically proven to be effective against SARS‐CoV‐2 and there are no standard treatment guidelines recommended by the WHO. The protease inhibitors lopinavir‐ritonavir can be considered, but the results of a recent clinical trial are discouraging.
 <xref rid="ppul24810-bib-0043" ref-type="ref">
  <sup>43</sup>
 </xref> Remdesivir and chloroquine have been shown to have good inhibitory effect on SARS‐CoV‐2 in vitro.
 <xref rid="ppul24810-bib-0044" ref-type="ref">
  <sup>44</sup>
 </xref> Remdesivir is now undergoing phase II clinical trials in treating patients with COVID‐19.
 <xref rid="ppul24810-bib-0045" ref-type="ref">
  <sup>45</sup>
 </xref> Hydroxychloroquine, sometimes in combination with azithromycin, has been widely used in both Europe and the US with little evidence of efficacy, and early analyses point to increased risk and higher mortality.
 <xref rid="ppul24810-bib-0046" ref-type="ref">
  <sup>46</sup>
 </xref>, 
 <xref rid="ppul24810-bib-0047" ref-type="ref">
  <sup>47</sup>
 </xref>
</p>
